Potvin S, Pampoulova T, Mancini-Marië A, Lipp O, Bouchard R-H, Stip E
Centre de recherche Fernand-Seguin, Hôpital Louis-H Lafontaine, 7331, rue Hochelaga, Montreal, Quebec, Canada H1N 3V2.
J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):796-8. doi: 10.1136/jnnp.2005.079228.
Few data have been gathered about the impact of psychoactive substances on extrapyramidal symptoms (EPS) in schizophrenia, and so far, inconsistent results have been reported. We studied 41 outpatients with schizophrenia (based on DSM-IV criteria), who were divided into two groups: with (n = 17) and without (n = 24) a substance use disorder (alcohol, cannabis, and/or cocaine). Both groups were matched for sociodemographic data and psychiatric symptoms (Positive and Negative Syndrome Scale). EPS were evaluated with the Extrapyramidal Symptoms Rating Scale and the Barnes Akathisia Scale, and all patients were stable on either quetiapine or clozapine. Patients receiving anticholinergic drugs were excluded. Analyses of variance were conducted on both groups and showed that schizophrenia patients with a comorbid substance use disorder (especially cocaine) displayed more EPS compared with non-abusing patients.
关于精神活性物质对精神分裂症锥体外系症状（EPS）的影响，所收集的数据很少，而且迄今为止，报告的结果并不一致。我们研究了41例符合《精神疾病诊断与统计手册》第四版（DSM-IV）标准的精神分裂症门诊患者，他们被分为两组：有物质使用障碍（酒精、大麻和/或可卡因，n = 17）和无物质使用障碍（n = 24）。两组在社会人口统计学数据和精神症状（阳性和阴性症状量表）方面进行了匹配。采用锥体外系症状评定量表和巴恩斯不安腿量表评估EPS，所有患者均稳定服用喹硫平或氯氮平。排除正在接受抗胆碱能药物治疗的患者。对两组进行方差分析，结果显示，与无物质滥用的患者相比，合并物质使用障碍（尤其是可卡因）的精神分裂症患者表现出更多的EPS。
